共 401 条
[1]
Romond EH(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
[2]
Perez EA(2005)Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[3]
Bryant J(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
[4]
Suman VJ(2005)Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820-7826
[5]
Geyer CE(2014)Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging European Heart Journal - Cardiovascular Imaging 15 1063-1093
[6]
Davidson NE(2008)Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26 1201-1203
[7]
Tan-Chiu E(2008)Effective doses in radiology and diagnostic nuclear medicine: a catalog Radiology 248 254-263
[8]
Martino S(2005)NT-ProBNP: the mechanism behind the marker J Card Fail 11 S81-S83
[9]
Paik S(2003)B-type natriuretic peptides. A diagnostic breakthrough in heart failure Minerva Cardioangiol 51 121-129
[10]
Kaufman PA(2011)Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients Br J Cancer 105 1663-1668